Myovant Sciences (Myovant Sciences) Equity-to-Asset : -1.38 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Myovant Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $-558.1 Mil. Myovant Sciences's Total Assets for the quarter that ended in Dec. 2022 was $403.5 Mil. Therefore, Myovant Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2022 was -1.38.

The historical rank and industry rank for Myovant Sciences's Equity-to-Asset or its related term are showing as below:

MYOV' s Equity-to-Asset Range Over the Past 10 Years
Min: -19.01 Med: -0.38 Max: 0.96
Current: -1.38

During the past 7 years, the highest Equity to Asset Ratio of Myovant Sciences was 0.96. The lowest was -19.01. And the median was -0.38.

MYOV's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs MYOV: -1.38

Myovant Sciences Equity-to-Asset Historical Data

The historical data trend for Myovant Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Equity-to-Asset Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Equity-to-Asset

Get a 7-Day Free Trial

0.32

0.03

-1.02

-0.49

-0.91

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Equity-to-Asset	Get a 7-Day Free Trial															-0.72	-0.91	-1.05	-1.06	-1.38

Competitive Comparison of Myovant Sciences's Equity-to-Asset

For the Biotechnology subindustry, Myovant Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Equity-to-Asset falls into.

Myovant Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Myovant Sciences's Equity to Asset Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Equity to Asset (A: Mar. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-473.477	/	520.011
	=	-0.91

Myovant Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Equity to Asset (Q: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-558.143	/	403.521
	=	-1.38

Myovant Sciences (NYSE:MYOV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Myovant Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957